Cue Biopharma (CUE)
Cue Biopharma received a Buy rating and a $33.00 price target from BTIG analyst Thomas Shrader on June 10. The company’s shares closed last Friday at $13.32, close to its 52-week low of $10.69.
According to TipRanks.com, Shrader is a 4-star analyst with an average return of 17.9% and a 45.0% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Checkmate Pharmaceuticals, Minerva Neurosciences, and Precision BioSciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cue Biopharma with a $30.75 average price target.
Mustang Bio (MBIO)
In a report issued on June 11, Justin Zelin from BTIG initiated coverage with a Buy rating on Mustang Bio and a price target of $11.00. The company’s shares closed last Friday at $3.79.
According to TipRanks.com, Zelin is a 3-star analyst with an average return of 11.4% and a 66.7% success rate. Zelin covers the Healthcare sector, focusing on stocks such as CASI Pharmaceuticals, Poseida Therapeutics, and Surface Oncology.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mustang Bio with a $10.50 average price target, representing a 162.5% upside. In a report issued on June 11, B.Riley Financial also maintained a Buy rating on the stock with a $13.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.